Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination.
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2012
At a glance
- Drugs Bortezomib; Panobinostat
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 25 Aug 2011 Planned end date changed from Jun 2013 to Feb 2011 as reported by ClinicalTrials.gov.
- 25 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.